Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Please find enclosed a Press Release on "Dr.
Reddy's Laboratories launches Versavo (bevacizumab) in the UK".
This is for your information and record.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer &
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | RICHA PERIWAL | USHA IYER |
| Hyderabad - 500034. Telangana, India. | richaperiwal@drreddys.com | ushaiyer@drreddys.com |
Reddy's Laboratories launches Versavo (bevacizumab) in the UK
Hyderabad India; March 19, 2024 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy's"),
a global pharmaceutical company announced the launch of Versavo (bevacizumab) in the United Kingdom (UK). Dr. Reddy's Versavo
is a (bevacizumab) biosimilar of Avastin 1 and indicated for the treatment of several types of cancers, including metastatic
colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced
cervical cancer, ovarian cancer and metastatic breast cancer2.
Versavo is the first Dr. Reddy's biosimilar
product to be approved and launched in the UK. It is available in strengths of 100mg and 400mg single use vials.
Dr. Reddy's launched Versavo in India
in 2019. Subsequently, Versavo was introduced in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand
name. In Colombia, the product was launched under the brand name Persivia .
Dr. Jayanth Sridhar, Global Head of Biologics
at Dr. Reddy's, said: "The launch of Versavo in a highly regulated market underscores our capability for global clinical
development of high-quality biosimilar products. Versavo is a potential treatment option for patients with different types of cancers.
This launch reinforces our commitment to bring more biosimilar and other critical biological products to meet the unmet needs of patients,
and strengthens our focus on oncology."
Dr. Reddy's Versavo :
is bevacizumab biosimilar from Dr. Reddy's. Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease progression
in patients with cancer. It is a humanized recombinant antibody that targets human vascular endothelial growth factor (VEGF), leading
to deterred angiogenesis and tumor growth3.
About Dr. Reddy's biosimilars programme:
Dr. Reddy's biosimilars business is part
of our key strategic initiatives expected to drive both near-term and long-term growth. Over the last 25 years, our Biologics team has
developed into a fully integrated organisation with robust capabilities in the development, manufacture and commercialisation of a range
of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some
products marketed in more than 25 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases
in various stages of development for global launches across regulated as well as emerging markets. We are also ramping up manufacturing
capacity to support our global expansion plans. In July 2023, our proposed rituximab biosimilar application was accepted for review by
the USFDA, EMA and MHRA.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,
India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good
Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars
and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep
science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter
of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high
in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions and
involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i)
general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition
and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the
impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets
addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics,
pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our
public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking
Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update
any information contained herein.